Foghorn Therapeutics, Inc. (FHTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.91-9.29%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · FHTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -67.7% |
| Our one-year growth estimate | diamond | -77.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 10.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
FHTX — strategy / product update — Costs Associated with Exit or Disposal Activities
Dated 2026-10-01
Costs Associated with Exit or Disposal Activities. On September 25, 2026, following review of clinical data from the Phase 1 trial of FHD-909, Foghorn Therapeutics Inc. (the “Company”) and Eli Lilly and Company (“Lilly”) made the decision not to advance the trial into the expansion phase. Further collaboration activities pursuant to the collaboration agreement between the Company and Lilly are not anticipated. As a result, Foghorn is prioritizing resources toward the programs in its portfolio…
Why it matters: A study delay already held up this program. A clear new plan would show the issue is resolved; more delay would add risk.
Watch forFoghorn gives a dated development plan for CBPd-171 and reports that the study issue is resolved.
Also watch forFoghorn reports another delay, no new timeline, or an end to CBPd-171 work.
Why it matters: The company plans a 40% workforce cut as it shifts money to its own programs. The next report can test if costs match that plan.
Watch forFoghorn reports lower costs and keeps its cash runway into the second half of 2029.
Also watch forCosts fail to fall, or Foghorn shortens its cash runway from the second half of 2029.
Why it matters: An IND filing would move a key company-owned cancer program toward human testing. A delay would slow the new pipeline plan.
Supportive ifFoghorn files an IND for its selective EP300 degrader in 2027.
Worry ifFoghorn says the EP300 IND target has slipped past 2027 or stops work on the program.
Why it matters: Foghorn says its cuts extend cash into the second half of 2029. The November 4 report can test that claim.
Watch forOn November 4, Foghorn confirms cash can fund operations into the second half of 2029.
Also watch forOn November 4, Foghorn gives a shorter cash runway or reports a need for new funding sooner.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$234 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $771 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,383 loss on $10,000 · 73.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.